Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CytomX Therapeutics
Biotech
Amgen, CytomX ax T-cell engager after assessing data, priorities
Amgen and CytomX have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities.
Nick Paul Taylor
Mar 7, 2025 5:39am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
CytomX lays off 40%, mulls future of Amgen-partnered drug
Jan 7, 2025 7:56am
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Mar 12, 2024 7:07am
Xencor pulls back from Genentech cancer pact to cut costs
Nov 8, 2023 6:00am
AbbVie sidelines CytomX after seeing midphase oncology ADC data
Mar 28, 2023 6:30am
